Semaglutide vs. tirzepatide for weight loss: sorting fact from TikTok hype

What's this video probably claiming?

Based on the hashtags and creator context, @anastasiaartemiou is likely walking through a comparison of semaglutide and tirzepatide for weight loss, possibly sharing personal experience or summarizing why one might work better than the other. These videos typically hit familiar beats: tirzepatide produces more weight loss, GLP-1s curb appetite by working on the brain, and these medications are changing how we treat obesity. Some creators in this space also touch on side effect management, dosing schedules, or cost differences between branded options like Wegovy, Ozempic, Mounjaro, and Zepbound. Without the transcript, we can't confirm specifics, but the hashtag combination strongly suggests a head-to-head framing, which is exactly where social media tends to oversimplify the clinical picture in ways that matter to real patients making real decisions.

What does the science actually show?

The data here is actually pretty compelling, so let's be precise about it. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at 15 mg produced a mean body weight reduction of 22.5% over 72 weeks in adults with obesity. That's striking. Semaglutide 2.4 mg, tested in the STEP 1 trial (Wilding et al., 2021, NEJM), produced about 14.9% mean weight loss over 68 weeks. A direct head-to-head trial called SURMOUNT-5 (2025, NEJM) confirmed tirzepatide's advantage, showing roughly 20% greater relative weight loss compared to semaglutide. Tirzepatide's edge comes from its dual mechanism: it agonizes both GLP-1 and GIP receptors, while semaglutide targets GLP-1 alone. Neither drug is appropriate for everyone, and neither produces results without meaningful lifestyle context. These are tools, not cures.

Where does the social media noise diverge from clinical reality?

Here's where TikTok content, even well-intentioned content, tends to go sideways. First, the weight loss numbers shared online almost always reflect the top-end trial results, not the distribution. In STEP 1, about 32% of participants lost less than 10% of body weight on semaglutide. That's a real subgroup that rarely gets mentioned. Second, the side effect conversation is often oversimplified. Nausea, vomiting, and gastrointestinal symptoms affect a substantial portion of patients, and the SURMOUNT and STEP trials both recorded discontinuation rates in the 4-7% range due to adverse events. Third, compounded versions of these drugs, which flooded the market during shortages, are not equivalent to FDA-approved branded formulations. Claiming otherwise, even implicitly, is misleading and potentially unsafe. The FDA has been explicit on this point. Social media rarely flags this distinction.

What should you actually know?

If you're watching GLP-1 content on TikTok to inform a medical decision, here's a grounded summary. Tirzepatide does appear to produce greater average weight loss than semaglutide based on trial data and a direct comparison. But individual response varies considerably, and the best drug for any person depends on their health history, insurance coverage, tolerance for side effects, and whether they have type 2 diabetes. Ozempic is FDA-approved for type 2 diabetes, not weight loss. Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) carry the weight management indication. These are not interchangeable labels on the same drug. Anyone considering these medications should be working with a licensed clinician who can evaluate their full picture, not calibrating expectations based on a 60-second comparison video. Access matters, and so does follow-up care.